WO1999051741A3 - Complexes de proteine lyst et proteines a interaction lyst - Google Patents

Complexes de proteine lyst et proteines a interaction lyst Download PDF

Info

Publication number
WO1999051741A3
WO1999051741A3 PCT/US1999/006831 US9906831W WO9951741A3 WO 1999051741 A3 WO1999051741 A3 WO 1999051741A3 US 9906831 W US9906831 W US 9906831W WO 9951741 A3 WO9951741 A3 WO 9951741A3
Authority
WO
WIPO (PCT)
Prior art keywords
lyst
protein
beta
complexes
lip10
Prior art date
Application number
PCT/US1999/006831
Other languages
English (en)
Other versions
WO1999051741A2 (fr
Inventor
Krishnan Nandabalan
Stephen Kingsmore
Original Assignee
Curagen Corp
Krishnan Nandabalan
Stephen Kingsmore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Krishnan Nandabalan, Stephen Kingsmore filed Critical Curagen Corp
Priority to AU32140/99A priority Critical patent/AU3214099A/en
Priority to CA002325562A priority patent/CA2325562A1/fr
Priority to JP2000542454A priority patent/JP2002510490A/ja
Priority to EP99914251A priority patent/EP1066378A2/fr
Publication of WO1999051741A2 publication Critical patent/WO1999051741A2/fr
Publication of WO1999051741A3 publication Critical patent/WO1999051741A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des complexes de la protéine LYST ou LYST-2, les protéines étant identifiées pour leur interaction avec LYST ou LYST-2 par un système d'analyse hybride à la levure. Les protéines interagissant avec LYST ou LYST-2 sont les protéines 14-3-3, HS1, Hrs, BMK1, KB07, Efs, XAP-4, OS9, caséine-kinase II bêta SU, calmoduline, troponine I, importine bêta, Fte-1, HERR1, imogène 38, atrophine-1, norbine, HBF-G2, DGS-I, GBDR1, la protéine contenant OPA, la protéine M4, LIP1, LIP2, LIP3, LIP4, LIP5, LIP6, LIP7, LIP8, LIP9, et LIP10. L'invention concerne donc des complexes de LYST ou LYST-2 et des protéines 14-3-3, la prétine HS1, Hrs, BMK1, KB07, Efs, XAP-4, OS9, caséine-kinase II bêta SU, calmoduline, troponine I, importine bêta, Fte-1, HERR1, imogène 38, atrophine-1, norbine, HBF-G2, DGS-I, GBDR1, la protéine contenant OPA, la protéine M4, LIP1, LIP2, LIP3, LIP4, LIP5, LIP6, LIP7, LIP8, LIP9, et LIP10, ainsi que des dérivés, des fragments, et des analogues de ceux-ci. Cette invention concerne également des acides nucléiques codant pour les protéines LIP1, LIP2, LIP3, LIP4, LIP5, LIP6, LIP7, LIP8, LIP9, et LIP10, ainsi que des dérivés, des fragments, et des analogues de ceux-ci. L'invention concerne en outre des méthodes de criblage de ces complexes ou de ces protéines, ces méthodes permettant de déterminer l'efficacité de ces complexes ou de ces protéines pour prévenir et/ou traiter certaines maladies et certains troubles, en particulier les maladies atopiques, les maladies auto-immunes, les maladies neurodégénératives, le cancer, les troubles de la pigmentation, les dysfonctionnements plaquettaires, et les maladies virales.
PCT/US1999/006831 1998-04-03 1999-03-29 Complexes de proteine lyst et proteines a interaction lyst WO1999051741A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU32140/99A AU3214099A (en) 1998-04-03 1999-03-29 Lyst protein complexes and lyst interacting proteins
CA002325562A CA2325562A1 (fr) 1998-04-03 1999-03-29 Complexes de proteine lyst et proteines a interaction lyst
JP2000542454A JP2002510490A (ja) 1998-04-03 1999-03-29 Ｌｙｓｔタンパク質複合体およびｌｙｓｔ相互作用タンパク質
EP99914251A EP1066378A2 (fr) 1998-04-03 1999-03-29 Complexes de proteine lyst et proteines a interaction lyst

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5495698A 1998-04-03 1998-04-03
US09/054,956 1998-04-03

Publications (2)

Publication Number Publication Date
WO1999051741A2 WO1999051741A2 (fr) 1999-10-14
WO1999051741A3 true WO1999051741A3 (fr) 1999-12-23

Family

ID=21994612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006831 WO1999051741A2 (fr) 1998-04-03 1999-03-29 Complexes de proteine lyst et proteines a interaction lyst

Country Status (5)

Country Link
EP (1) EP1066378A2 (fr)
JP (1) JP2002510490A (fr)
AU (1) AU3214099A (fr)
CA (1) CA2325562A1 (fr)
WO (1) WO1999051741A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN111269919B (zh) * 2020-03-19 2021-07-13 四川农业大学 玉米基因ZmLIP2及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2542171C (fr) 2002-06-26 2015-12-15 Abbott Gmbh & Co. Kg Modulateurs et modulation de l'interaction entre les rgm et la neogenine
EP2053409A1 (fr) 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Marqueurs spécifiques du syndrome métabolique
WO2005094571A1 (fr) * 2004-03-31 2005-10-13 Japan Science And Technology Agency Animal génétiquement modifié et méthode de mesure de l'exocytose à l'aide de l'animal
ES2542501T3 (es) 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
GB0903913D0 (en) * 2009-03-06 2009-04-22 Medical Res Council Compositions and methods
SG181563A1 (en) 2009-12-08 2012-07-30 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011083147A1 (fr) 2010-01-08 2011-07-14 Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh Inhibition de wave1 dans l'intervention médicale de maladies inflammatoires et/ou d'infections causées par un pathogène
WO2011131626A1 (fr) 2010-04-19 2011-10-27 Medizinische Universität Innsbruck Tmem195 code pour l'activité alkylglycérol monooxygénase dépendante de la tétrahydrobioptérine
RU2644337C2 (ru) 2012-01-27 2018-02-08 Эббви Дойчланд Гмбх Унд Ко. Кг Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов
CN106456771B9 (zh) * 2014-05-02 2021-07-20 国家儿童医院研究所 用于抗lyst免疫调节的组合物和方法
WO2017100782A1 (fr) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Systèmes et procédés pour greffons vasculaires de génie tissulaire optimisés spécifiques à un patient
CA3008434A1 (fr) 2015-12-14 2017-06-22 Rowan University Biomarqueurs d'autoanticorps de la maladie d'alzheimer au stade precoce, antigenes cibles et utilisations diagnostiques associees
JP6899201B2 (ja) * 2016-06-23 2021-07-07 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029407A2 (fr) * 1995-03-23 1996-09-26 Incyte Pharmaceuticals, Inc. Homologues de cellubrevines
WO1997028262A1 (fr) * 1996-02-01 1997-08-07 University Of Florida Compositions de genes lyst1 et lyst2 et leurs procedes d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029407A2 (fr) * 1995-03-23 1996-09-26 Incyte Pharmaceuticals, Inc. Homologues de cellubrevines
WO1997028262A1 (fr) * 1996-02-01 1997-08-07 University Of Florida Compositions de genes lyst1 et lyst2 et leurs procedes d'utilisation

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BARBOSA M D F S ET AL: "IDENTIFICATION OF THE HOMOLOGOUS BEIGE AND CHEDIAK-HIGASHI SYNDROME GENES", NATURE, vol. 382, no. 6588, 18 July 1996 (1996-07-18), pages 262 - 265, XP002032769, ISSN: 0028-0836 *
BARBOSA M D F S ET AL: "THE RAB PROTEIN FAMILY: GENETIC MAPPING OF SIX RAB GENES IN THE MOUSE", GENOMICS, vol. 30, no. 3, 10 December 1995 (1995-12-10), pages 439 - 444, XP000674357, ISSN: 0888-7543 *
CHIEN C -T ET AL: "THE TWO-HYBRID SYSTEM: A METHOD TO IDENTIFY AND CLONE GENES FOR PROTEINS THAT INTERACT WITH A PROTEIN OF INTEREST", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 88, November 1991 (1991-11-01), pages 9578 - 9582, XP002913781, ISSN: 0027-8424 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 14 March 1994 (1994-03-14), HINXTON, GB, XP002120655 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 15 January 1995 (1995-01-15), HINXTON, GB, XP002120657 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 2 March 1995 (1995-03-02), HINXTON, GB, XP002120650 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 25 August 1995 (1995-08-25), HINXTON, GB, XP002120652 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 29 January 1994 (1994-01-29), HINXTON, GB, XP002120653 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 31 January 1996 (1996-01-31), HINXTON, GB, XP002120656 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 31 May 1991 (1991-05-31), HINXTON, GB, XP002120651 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 4 June 1997 (1997-06-04), HINXTON, GB, XP002120654 *
PEROU C M ET AL: "COMPLEMENTATION ANALYSIS OF CHEDIAK-HIGASHI SYNDROME: THE SAME GENE MAY BE RESPONSABLE FOR THE DEFECT IN ALL PATIENTS AND SPECIES", SOMATIC CELL AND MOLECULAR GENETICS, vol. 19, no. 5, 1 September 1993 (1993-09-01), pages 459 - 468, XP000674425 *
PEROU C M ET AL: "IDENTIFICATION OF THE MURINE BEIGE GENE BY YAC COMPLEMENTATION AND POSITIONAL CLONING", NATURE GENETICS, vol. 13, no. 3, 1 July 1996 (1996-07-01), pages 303 - 308, XP000674628, ISSN: 1061-4036 *
PEVSNER J ET AL: "Mammalian homologues of yeast vacuolar protein sorting (vps) genes implicated in Golgi-to-lysosome trafficking", GENE, vol. 183, no. 1, 1 January 1996 (1996-01-01), pages 7-14, XP004062720, ISSN: 0378-1119 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN111269919B (zh) * 2020-03-19 2021-07-13 四川农业大学 玉米基因ZmLIP2及其应用

Also Published As

Publication number Publication date
AU3214099A (en) 1999-10-25
EP1066378A2 (fr) 2001-01-10
JP2002510490A (ja) 2002-04-09
WO1999051741A2 (fr) 1999-10-14
CA2325562A1 (fr) 1999-10-14

Similar Documents

Publication Publication Date Title
WO1999051741A3 (fr) Complexes de proteine lyst et proteines a interaction lyst
WO2002102993A3 (fr) Proteines secretees par l'homme
IL124728A0 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
IL221367A (en) Isolated nucleic acid encoding a toll-like homologous protein and a toll-like homologous protein preparation process
EP0832973A3 (fr) Protéine de liaison de GTP
WO1999015657A3 (fr) Complexes de 53bp2
WO1998041629A3 (fr) Recepteur 5 contenant un domaine de mort
CA2158750A1 (fr) Anticorps monoclonaux diriges contre les polypeptides de la caseine-kinase i
AU7566396A (en) Process for the preparation of peptides by way of streptavidin fusion proteins
DE69434166D1 (de) Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen
WO2001055308A3 (fr) Acides nucleiques, proteines et anticorps
FR2697525B1 (fr) Peptides de fusion ayant une activité de liaison à la streptavidine.
WO1999037788A3 (fr) Diagnostic et traitement de maladies associees a aur1 et/ou aur2
WO1995021919A3 (fr) Proteine a activite de thrombopoietine (tpo)
CA2135208A1 (fr) Proteines fixatrices de l'immunoglobuline, derivees de la proteine l, et leur utilisation
WO2001054472A8 (fr) Acides nucleiques, proteines et anticorps
WO2002077013A3 (fr) Proteines secretees humaines
EP0871661A4 (fr) Nouveau domaine proteinique fixant des proteines tyrosine-phosphorylees
AU5596998A (en) Pyk2 related products and methods
AU3346289A (en) Heparin-binding proteins, DNA coding for them, processes for producing them as well as therapeutic preparations containing them
EP0897002A3 (fr) U62317, une protéine avec un domaine se liant à JNK
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
WO1997002730A3 (fr) Polypeptide associe a une matrice d'email
EP1023906A4 (fr) Potentialisateur pour anticorps anti-tumeur lymphoide
AU1409795A (en) Process for making undenatured whey protein concentrate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09582687

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2325562

Country of ref document: CA

Ref country code: CA

Ref document number: 2325562

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 542454

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 32140/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999914251

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999914251

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999914251

Country of ref document: EP